Video

Coverage From the 2012 NCONN Conference

Author(s):

OncLive presents live coverage from the 2012 NCONN Changing the Face of Cancer Care Conference, held at the Gaylord Opryland Hotel from October 4th to 6th, in Nashville, TN.

OncLive presents live coverage from the 2012 National Coalition of Oncology Nurse Navigators' (NCONN) annual conference, Changing the Face of Cancer Care, held at the Gaylord Opryland Hotel from October 4th to 6th, in Nashville, Tennessee.

Presentations and breakout sessions at the NCONN meeting feature expert insight into the optimal multidisciplinary management of patients with cancer.

The meeting seeks to address the real-time needs of oncology nurses, oncology nurse navigators, clinical nurse specialists, social workers, community healthcare workers, and patient navigators.

OncLive’s conference coverage features video interviews with leading specialists and articles highlighting the top presentations from the meeting.

For more information on NCONN, visit nconn.org.

Not signed up to receive OncLive emails? Make an account today to make sure that you don't miss updates from our conference coverage. Register now!

<<<

View coverage from the 2012 NCONN Conference

Related Videos
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School